Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 21;14(2):384-397.
doi: 10.1021/acssynbio.4c00569. Epub 2025 Feb 3.

Characterization of Rationally Designed CRISPR/Cas9-Based DNA Methyltransferases with Distinct Methyltransferase and Gene Silencing Activities in Human Cell Lines and Primary Human T Cells

Affiliations

Characterization of Rationally Designed CRISPR/Cas9-Based DNA Methyltransferases with Distinct Methyltransferase and Gene Silencing Activities in Human Cell Lines and Primary Human T Cells

Rosa Selenia Guerra-Resendez et al. ACS Synth Biol. .

Abstract

Nuclease-deactivated Cas (dCas) proteins can be used to recruit epigenetic effectors, and this class of epigenetic editing technologies has revolutionized the ability to synthetically control the mammalian epigenome and transcriptome. DNA methylation is one of the most important and well-characterized epigenetic modifications in mammals, and while many different forms of dCas-based DNA methyltransferases (dCas-DNMTs) have been developed for programmable DNA methylation, these tools are frequently poorly tolerated and/or lowly expressed in mammalian cell types. Further, the use of dCas-DNMTs has largely been restricted to cell lines, which limits mechanistic insights in karyotypically normal contexts and hampers translational utility in the longer term. Here, we extend previous insights into the rational design of the catalytic core of the mammalian DNMT3A methyltransferase and test three dCas9-DNMT3A/3L variants across different human cell lines and in primary donor-derived human T cells. We find that mutations within the catalytic core of DNMT3A stabilize the expression of dCas9-DNMT3A/3L fusion proteins in Jurkat T cells without sacrificing DNA methylation or gene-silencing performance. We also show that these rationally engineered mutations in DNMT3A alter DNA methylation profiles at loci targeted with dCas9-DNMT3A/3L in cell lines and donor-derived human T cells. Finally, we leverage the transcriptionally repressive effects of dCas9-DNMT3A/3L variants to functionally link the expression of a key immunomodulatory transcription factor to cytokine secretion in donor-derived T cells. Overall, our work expands the synthetic biology toolkit for epigenetic editing and provides a roadmap for the use of engineered dCas-based DNMTs in primary mammalian cell types.

Keywords: CRISPR/Cas systems; DNA methylation; dCas9; epigenetic editing; human T cells; rational mutagenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): MDE and IBH are inventors on patents related to genome and epigenome editing technologies. The remaining authors declare no conflict of interest.

References

    1. Goell J. H.; Hilton I. B. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility. Trends Biotechnol 2021, 39 (7), 678–691. 10.1016/j.tibtech.2020.10.012. - DOI - PubMed
    1. Bashor C. J.; Hilton I. B.; Bandukwala H.; Smith D. M.; Veiseh O. Engineering the next Generation of Cell-Based Therapeutics. Nat. Rev. Drug Discovery 2022, 21 (9), 655–675. 10.1038/s41573-022-00476-6. - DOI - PMC - PubMed
    1. McCutcheon S. R.; Rohm D.; Iglesias N.; Gersbach C. A. Epigenome Editing Technologies for Discovery and Medicine. Nat. Biotechnol 2024, 42 (8), 1199–1217. 10.1038/s41587-024-02320-1. - DOI - PubMed
    1. Gilbert L. A.; Larson M. H.; Morsut L.; Liu Z.; Brar G. A.; Torres S. E.; Stern-Ginossar N.; Brandman O.; Whitehead E. H.; Doudna J. A.; Lim W. A.; Weissman J. S.; Qi L. S. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell 2013, 154 (2), 442–451. 10.1016/j.cell.2013.06.044. - DOI - PMC - PubMed
    1. Perez-Pinera P.; Kocak D. D.; Vockley C. M.; Adler A. F.; Kabadi A. M.; Polstein L. R.; Thakore P. I.; Glass K. A.; Ousterout D. G.; Leong K. W.; Guilak F.; Crawford G. E.; Reddy T. E.; Gersbach C. A. RNA-Guided Gene Activation by CRISPR-Cas9-Based Transcription Factors. Nat. Methods 2013, 10 (10), 973–976. 10.1038/nmeth.2600. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources